Besides the potential to more comprehensively understand the regulation of p97 by its cofactors, a PPI inhibitor targeting the interaction between p97 and SHP-motif containing cofactors would yield a promising strategy to modulate the degradation of ubiquitylated proteins, with the ultimate promise of a new strategy to treat cancer. This evidence concerns the gene VCP and cancer.